Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...
Socioeconomic and demographic factors impact surgical outcomes in upper extremity soft tissue sarcomas, affecting amputation ...
Immunotherapy making inroads into advanced endometrial cancer management: A single center real world experience. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
An annual report from the American Cancer Society shows that, for the first time, over 70% of Americans diagnosed with cancer ...
The five-year survival rate for all cancers combined in the US reached a landmark 70% for Americans diagnosed between 2015 ...
Fragmented care - receiving medical treatment at more than one facility - has been associated with both positive and negative outcomes for cancer patients depending on a number of factors such as ...
Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...
The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...
COLUMBUS, Ohio – Pancreatic cancer blood tests, genetic predictors of breast cancer survival and sarcoma treatment response prediction tools are among the research topics being presented by scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results